Skip to main content

Research Repository

Advanced Search

Discovery of Novel Tacrine–Pyrimidone Hybrids as Potent Dual AChE/GSK-3 Inhibitors for the Treatment of Alzheimer’s Disease

Yao, Hong; Uras, Giuseppe; Zhang, Pengfei; Xu, Shengtao; Yin, Ying; Liu, Jie; Qin, Shuai; Li, Xinuo; Allen, Stephanie; Bai, Renren; Gong, Qi; Zhang, Haiyan; Zhu, Zheying; Xu, Jinyi

Discovery of Novel Tacrine–Pyrimidone Hybrids as Potent Dual AChE/GSK-3 Inhibitors for the Treatment of Alzheimer’s Disease Thumbnail


Authors

Hong Yao

Giuseppe Uras

Pengfei Zhang

Shengtao Xu

Ying Yin

Jie Liu

Shuai Qin

Xinuo Li

Stephanie Allen

Renren Bai

Qi Gong

Haiyan Zhang

ZHEYING ZHU Zheying.Zhu@nottingham.ac.uk
Associate Professor in International Pharmacy and Traditional Medicines

Jinyi Xu



Abstract

Based on a multitarget strategy, a series of novel tacrine–pyrimidone hybrids were identified for the potential treatment of Alzheimer’s disease (AD). Biological evaluation results demonstrated that these hybrids exhibited significant inhibitory activities toward acetylcholinesterase (AChE) and glycogen synthase kinase 3 (GSK-3). The optimal compound 27g possessed excellent dual AChE/GSK-3 inhibition both in terms of potency and equilibrium (AChE: IC50 = 51.1 nM; GSK-3β: IC50 = 89.3 nM) and displayed significant amelioration on cognitive deficits in scopolamine-induced amnesia mice and efficient reduction against phosphorylation of tau protein on Ser-199 and Ser-396 sites in glyceraldehyde (GA)-stimulated differentiated SH-SY5Y cells. Furthermore, compound 27g exhibited eligible pharmacokinetic properties, good kinase selectivity, and moderate neuroprotection against GA-induced reduction in cell viability and neurite damage in SH-SY5Y-derived neurons. The multifunctional profiles of compound 27g suggest that it deserves further investigation as a promising lead for the prospective treatment of AD.

Citation

Yao, H., Uras, G., Zhang, P., Xu, S., Yin, Y., Liu, J., …Xu, J. (2021). Discovery of Novel Tacrine–Pyrimidone Hybrids as Potent Dual AChE/GSK-3 Inhibitors for the Treatment of Alzheimer’s Disease. Journal of Medicinal Chemistry, 64(11), 7483-7506. https://doi.org/10.1021/acs.jmedchem.1c00160

Journal Article Type Article
Acceptance Date May 12, 2021
Online Publication Date May 23, 2021
Publication Date Jun 10, 2021
Deposit Date May 25, 2021
Publicly Available Date May 24, 2022
Journal Journal of Medicinal Chemistry
Print ISSN 0022-2623
Electronic ISSN 1520-4804
Publisher American Chemical Society
Peer Reviewed Peer Reviewed
Volume 64
Issue 11
Pages 7483-7506
DOI https://doi.org/10.1021/acs.jmedchem.1c00160
Keywords Molecular Medicine; Drug Discovery
Public URL https://nottingham-repository.worktribe.com/output/5572177
Publisher URL https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00160
Additional Information This document is the Accepted Manuscript version of a Published Work that appeared in final form in Journal of Medicinal Chemistry, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00160

Files





Downloadable Citations